secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K/A
Filed at:   2024-06-24T23:59:59+00:00
Accession:  0001213900-24-055288
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharm amends ophthalmology license deal to allow incremental milestone payments
--------------------------------------------------------------------------------

- ABVC and BIOFIRST amended licensing agreement with ForSeeCon Eye Corp (FEYE) covering ophthalmology pipeline including Vitargus.
- Second milestone payment of $3.5M can now be paid incrementally (e.g., $100k) at any time, rather than a single lump sum.
- Amendment dated June 18, 2024; all other terms of the original March 25, 2024, license remain unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024055288/0001213900-24-055288-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024055288/ea0208383-8ka1_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-055288

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer